486 related articles for article (PubMed ID: 10914849)
21. Hospitalizations for upper and lower GI events associated with traditional NSAIDs and acetaminophen among the elderly in Quebec, Canada.
Rahme E; Barkun A; Nedjar H; Gaugris S; Watson D
Am J Gastroenterol; 2008 Apr; 103(4):872-82. PubMed ID: 18371130
[TBL] [Abstract][Full Text] [Related]
22. Gastroprotective therapy and risk of gastrointestinal ulcers: risk reduction by COX-2 therapy.
Wolfe F; Anderson J; Burke TA; Arguelles LM; Pettitt D
J Rheumatol; 2002 Mar; 29(3):467-73. PubMed ID: 11908558
[TBL] [Abstract][Full Text] [Related]
23. Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo.
Bensen WG; Zhao SZ; Burke TA; Zabinski RA; Makuch RW; Maurath CJ; Agrawal NM; Geis GS
J Rheumatol; 2000 Aug; 27(8):1876-83. PubMed ID: 10955327
[TBL] [Abstract][Full Text] [Related]
24. A double blind study comparing the efficacy and safety of enteric coated naproxen to naproxen in the management of NSAID intolerant patients with rheumatoid arthritis and osteoarthritis. Naproxen EC Study Group.
Caldwell JR; Roth SH
J Rheumatol; 1994 Apr; 21(4):689-95. PubMed ID: 8035394
[TBL] [Abstract][Full Text] [Related]
25. Assessment of gastrointestinal and cardiovascular risk in patients with osteoarthritis who require NSAIDs: the LOGICA study.
Lanas A; Tornero J; Zamorano JL
Ann Rheum Dis; 2010 Aug; 69(8):1453-8. PubMed ID: 20498210
[TBL] [Abstract][Full Text] [Related]
26. Risk factors for serious nonsteroidal-induced gastrointestinal complications: regression analysis of the MUCOSA trial.
Simon LS; Hatoum HT; Bittman RM; Archambault WT; Polisson RP
Fam Med; 1996 Mar; 28(3):204-10. PubMed ID: 8900554
[TBL] [Abstract][Full Text] [Related]
27. NSAID gastropathy: the second most deadly rheumatic disease? Epidemiology and risk appraisal.
Fries JF
J Rheumatol Suppl; 1991 Mar; 28():6-10. PubMed ID: 2038014
[TBL] [Abstract][Full Text] [Related]
28. Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis.
Goldstein JL; Correa P; Zhao WW; Burr AM; Hubbard RC; Verburg KM; Geis GS
Am J Gastroenterol; 2001 Apr; 96(4):1019-27. PubMed ID: 11316141
[TBL] [Abstract][Full Text] [Related]
29. Appropriateness of NSAID and Coxib prescribing for patients with osteoarthritis by primary care physicians in Ontario: results from the CANOAR study.
Sebaldt RJ; Petrie A; Goldsmith CH; Marentette MA
Am J Manag Care; 2004 Nov; 10(11 Pt 1):742-50. PubMed ID: 15623264
[TBL] [Abstract][Full Text] [Related]
30. The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis.
Maetzel A; Krahn M; Naglie G
Arthritis Rheum; 2003 Jun; 49(3):283-92. PubMed ID: 12794781
[TBL] [Abstract][Full Text] [Related]
31. Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis.
Solomon DH; Avorn J; Katz JN; Weinblatt ME; Setoguchi S; Levin R; Schneeweiss S
Arthritis Rheum; 2006 Dec; 54(12):3790-8. PubMed ID: 17136752
[TBL] [Abstract][Full Text] [Related]
32. Consequences of increased systolic blood pressure in patients with osteoarthritis and rheumatoid arthritis.
Singh G; Miller JD; Huse DM; Pettitt D; D'Agostino RB; Russell MW
J Rheumatol; 2003 Apr; 30(4):714-9. PubMed ID: 12672188
[TBL] [Abstract][Full Text] [Related]
33. Complications of nonsteroidal antiiflammatory drug gastropathy and use of gastric cytoprotection: experience at a tertiary care health center.
Bakowsky VS; Hanly JG
J Rheumatol; 1999 Jul; 26(7):1557-63. PubMed ID: 10405945
[TBL] [Abstract][Full Text] [Related]
34. Rates and predictors of herpes zoster in patients with rheumatoid arthritis and non-inflammatory musculoskeletal disorders.
Wolfe F; Michaud K; Chakravarty EF
Rheumatology (Oxford); 2006 Nov; 45(11):1370-5. PubMed ID: 17003175
[TBL] [Abstract][Full Text] [Related]
35. Jaw pain: its prevalence and meaning in patients with rheumatoid arthritis, osteoarthritis, and fibromyalgia.
Wolfe F; Katz RS; Michaud K
J Rheumatol; 2005 Dec; 32(12):2421-8. PubMed ID: 16331775
[TBL] [Abstract][Full Text] [Related]
36. Nonsteroidal antiinflammatory drug use among patients with GI bleeding.
Dominick KL; Bosworth HB; Jeffreys AS; Grambow SC; Oddone EZ; Horner RD
Ann Pharmacother; 2004; 38(7-8):1159-64. PubMed ID: 15187205
[TBL] [Abstract][Full Text] [Related]
37. Gastrointestinal prophylactic therapy among patients with arthritis treated by rheumatology specialists.
Garcia EB; Michaud K; Wolfe F
J Rheumatol; 2006 Apr; 33(4):779-84. PubMed ID: 16511939
[TBL] [Abstract][Full Text] [Related]
38. An evidence-based approach to prescribing nonsteroidal antiinflammatory drugs. Third Canadian Consensus Conference.
Tannenbaum H; Bombardier C; Davis P; Russell AS;
J Rheumatol; 2006 Jan; 33(1):140-57. PubMed ID: 16331802
[TBL] [Abstract][Full Text] [Related]
39. A novel composite endpoint to evaluate the gastrointestinal (GI) effects of nonsteroidal antiinflammatory drugs through the entire GI tract.
Chan FK; Cryer B; Goldstein JL; Lanas A; Peura DA; Scheiman JM; Simon LS; Singh G; Stillman MJ; Wilcox CM; Berger MF; Breazna A; Dodge W
J Rheumatol; 2010 Jan; 37(1):167-74. PubMed ID: 19884267
[TBL] [Abstract][Full Text] [Related]
40. Increase in cardiovascular and cerebrovascular disease prevalence in rheumatoid arthritis.
Wolfe F; Freundlich B; Straus WL
J Rheumatol; 2003 Jan; 30(1):36-40. PubMed ID: 12508387
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
